ERBB2 and non-small cell lung carcinoma: DESTINY-Lung02 confirmed T-DXd efficacy for pre-treated patients with HER2-mutant NSCLC and investigated appropriate dose regimens to reduce TRAEs such as interstitial pneumonia (5.9% vs. 14%), confirming that T-DXd may become a treatment of choice in this disease [41].